

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

Figure 1A: Retention of Activity by PEGylated *Candida* Uricase




Figure 1B: Retention of Activity by PEGylated *Candida* Uricase




Figure 2A: Retention of Activity by PEGylated Porcine Uricase




Figure 2B: Retention of Activity by PEGylated Porcine Uricase





Figure 3A: Retention of Activity by PEGylated PBC Uricase



PEG-URIC ACID OXIDASE CONJUGATES AND USE THEREOF

Williams, et al.

Appl. No.: 09/839946 Atty Docket: MVIEWD.1A2DV1

Figure 3B: Retention of Activity by PEGylated PBC Uricase




Figure 4A:
Retention of Activity by PEGylated Uricozyme® (*A. flavus* Uricase)




Figure 4B:
Retention of Activity by PEGylated Uricozyme® (*A. flavus* Uricase)




Figure 5A: Retention of Activity by PEGylated Soybean Uricase





Figure 5B: Retention of Activity by PEGylated Soybean Uricase



PEROXYDASE CONJUGATES AND USE THEREOF

Williams, et al.

Appl. No.: 09/839946 Atty Docket: MVIEWD.1A2DVI

Figure 6: Deduced amino acid sequences of Pig-Baboon Chimeric (PBC) uricase, PBC uricase that is truncated at the amino and carboxyl terminals (PBC-NT-CT) and Porcine uricase containing the mutations R291K and T301S (PKS Uricase) (SEQ ID NO:3), compared with the porcine sequence (SEQ ID NO: 1) and baboon sequence (SEQ ID NO: 2)

Porcine	MAHYRNDYKK	NDEVEFVRTG	YGKDMIKVLH	IQRDGKYHSI	40
PBC	<i>porcine sequence 1-225</i> →				40
PBC-NT-CT	<i>porcine sequence 1-219</i> →				34
PKS	<i>porcine sequence 1-288</i> →				40
Baboon	MADYHNNYKK	NDELEFVRTG	YGKDMVKVLH	IQRDGKYHSI	40
Porcine	KEVATSVQLT	LSSKKDYLHG	DNSDVIPTDT	IKNTVNVLAK	80
PBC	<i>porcine sequence</i> →				80
PBC-NT-CT	<i>porcine sequence</i> →				74
PKS	<i>porcine sequence</i> →				80
Baboon	KEVATSVQLT	LSSKKDYLHG	DNSDIIPTDT	IKNTVHVLAK	80
Porcine	FKGIKSIETF	AVTICEHFLS	SFKHVIRAQV	YVEEVPKRF	120
PBC	<i>porcine sequence</i> →				120
PBC-NT-CT	<i>porcine sequence</i> →				114
PKS	<i>porcine sequence</i> →				120
Baboon	FKGIKSIEAF	GVNICEYFLS	SFNHVIRAQV	YVEEIPWKRL	120
Porcine	EKNGVKHVHA	FIYTPTGTHF	CEVEQIRNGP	PVIHSGIKDL	160
PBC	<i>porcine sequence</i> →				160
PBC-NT-CT	<i>porcine sequence</i> →				154
PKS	<i>porcine sequence</i> →				160
Baboon	EKNGVKHVHA	FIHTPTGTHF	CEVEQLRSGP	PVIHSGIKDL	160
Porcine	KVLKTTQSGF	EGFIKDQFTT	LPEVKDRFCFA	TQVYCKWRYH	200
PBC	<i>porcine sequence</i> →				200
PBC-NT-CT	<i>porcine sequence</i> →				194
PKS	<i>porcine sequence</i> →				200
Baboon	KVLKTTQSGF	EGFIKDQFTT	LPEVKDRFCFA	TQVYCKWRYH	200
Porcine	QGRDVDFEAT	WDTVRSIVLQ	KFAGPYDKGE	YSPSVQKTLY	240
PBC	<i>porcine sequence</i> →		→ ← <i>baboon sequence</i>		240
PBC-NT-CT	<i>porcine sequence</i> →		→ ← <i>baboon sequence</i>		234
PKS	<i>porcine sequence</i> →				240
Baboon	QCRDVDFEAT	WTGIRDLVLE	KFAGPYDKGE	YSPSVQKTLY	240
Porcine	DIQVLTGQV	PEIEDMEISL	PNIHYLNIDM	SKMGLINKEE	280
PBC	<i>baboon sequence</i> →				280
PBC-NT-CT	<i>baboon sequence</i> →				274
PKS	<i>porcine sequence</i> →				280
Baboon	DIQVLSLSRV	PEIEDMEISL	PNIHYFNIDM	SKMGLINKEE	280
Porcine	VLLPLDNPYG	RITGTVKRKL	TSRL	304	
PBC	<i>baboon sequence</i> →			304	
PBC-NT-CT	<i>baboon sequence</i> →			295	
PKS	<i>porcine</i> ← <i>baboon</i> →			304	
Baboon	VLLPLDNPYG	KITGTVKRKL	SSRL	304	

Figure 7: Serum Uricase Activity 24 Hours after Each PEG-Uricase Injection, Relative to the First Injection






Figure 8: Inverse Relationship between Serum PEG-Uricase Activity and Uric Acid Levels in the Serum and Urine of a Uricase-Deficient Mouse



**Figure 9: Decreased Severity of Urine-Concentrating Defect
in Uricase-Deficient Mice Treated with PEG-Uricase**



098339946 071602

PEROXYDASE CONJUGATES AND USE THEREOF

Williams, et al.

Appl. No.: 09/839946

Atty Docket: MVIEWD.1A2DV1

Figure 10: Decreased Severity of Nephrogenic Diabetes Insipidus
in Uricase-Deficient Mice Treated with PEG-Uricase





Figure 11:

Decreased Severity of Uric Acid-Induced Nephropathy after Treatment with PEG-Uricase, as Visualized by Magnetic Resonance Microscopy



© M. Delnomdedieu, 1997 - Ctr. For In Vivo Microscopy - Duke Univ. Med. Ctr.



PEO GLUCURONATE OXIDASE CONJUGATES AND USE THEREOF
Williams, et al.
Appl. No.: 09/839946 Atty Docket: MVIEWD.1A2DV1

Figure 12: Clearance from the Circulation of BALB/c Mice of PBC Uricase Tetramer and Octamer Coupled to 5-6 Strands of 10-kDa PEG/Subunit

